NCT07471815 2026-03-13
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Harbin Medical University
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT00567606 2023-11-30
Prevention of Osteoporosis in Breast Cancer Survivors
University of Nebraska
Phase NA Completed
NCT03861091 2023-07-27
Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT
Wake Forest University Health Sciences
Phase 2 Completed
NCT00452439 2020-12-28
A Study of Actonel for the Prevention of Bone Loss
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00859027 2018-05-01
Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
UConn Health
Phase 4 Completed
NCT00485953 2017-10-13
REBBeCA II
University of Pittsburgh
Phase 4 Completed
NCT00043069 2016-12-07
Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00054418 2016-07-13
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00216060 2016-05-26
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
Hoosier Cancer Research Network
Phase 3 Terminated
NCT00118508 2015-08-13
The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)
University of Pittsburgh
Phase NA Completed
NCT00859703 2013-10-31
RISAROS
Hospices Civils de Lyon
Phase 3 Completed
NCT00145704 2013-04-08
Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density
State University of New York - Upstate Medical University
Phase NA Terminated
NCT00426777 2012-02-03
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
CMX Research
Phase 3 Completed